Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-30
2011-12-13
Murray, Jeffrey (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S263000
Reexamination Certificate
active
08076344
ABSTRACT:
The present invention relates to compounds of formula (I):wherein R1, R2, and R3, are defined herein. Pharmaceutical compositions and methods for treating DGAT-1related diseases or conditions are also disclosed.
REFERENCES:
patent: 2779799 (1957-01-01), Hamlin
patent: 6100077 (2000-08-01), Sturley et al.
patent: 7091228 (2006-08-01), Smith et al.
patent: 1149835 (2001-10-01), None
patent: WO-0139773 (2001-06-01), None
patent: WO-2006078676 (2006-07-01), None
patent: WO-2006092414 (2006-09-01), None
patent: WO-2006092428 (2006-09-01), None
Wolff et. al., “Burger's Medicinal Chemistry and Drug Discovery,” 5th Ed. Part 1, pp. 975-977 (1995).
Banker, et. al., Modern Pharmaceuticals, (1996), p. 596.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Ahn JH, Joung MJ, Yoon NM, “A New Method of Synthesis for Propargylic Amines and Ethers via Benzotriazole Derivatives Using Sodium Dialkynyldiethylaluminates”, J Org Chem, 1999, 64, 488-492.
Belotti D. et al., “Synthesis of Bicyclic Cyclopentanols by Photoreductive Cyclization of 6,e-Unsaturated Ketones,” J. Org. Chem., 1986, pp. 4196-4200, vol. 51.
Buhman KK, Smith SJ, Stone SJ, et al., “DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis”, J Biol Chem, 2002, 277/28, 25474-9.
Burgess Kevin et al., “Chiral 1,3-Cyclobutane Amino Adds: Syntheses and Extended Conformations,” Tetrahedron Letters, 1997, pp. 1681-1684, vol. 38 (10), Elsevier Science.
Cases S, Smith SJ, Zheng YW, et al., “Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis”, Proc Natl Acad Sci, 1998, 95/22, 13018-13023.
Cases S, Stone SJ, Zhou P, et al., “Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members”, J Biol Chem, 2001, 276/42, 38870-6.
Chen HC, Farese RV Jr, “Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice”, Arterioscler Thromb Vasc Biol, 2005, 25/3, 482-6.
Chen HC, Farese RV Jr., “DGAT and triglyceride synthesis: a new target for obesity treatment?”, Trends Cardiovasc Med, 2000, 10/5, 188-92.
Chen HC, Smith SJ, Ladha Z, et al., “Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1”, J Clin Invest, 2002, 109/8, 1049-55.
Collins S, Martin TL, Surwit RS, Robidoux J, “Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics”, Physiol Behav, 2004, 81/2, 243-8.
Dufey, Pierre, “On the preparation of 2-alkyl hexahydrochromanols,” P. Bull. Soc. Chim. Fr., 1968, pp. 4653-4662.
Greene, T.W. et al., “Protective Groups in Organic Synthesis,” 1999, 4 Pages, 3 rd Ed, John Wiley & Sons.
Grundy SM, “Metabolic complications of obesity”, Endocrine, 2000, 13/2, 155-165.
Harada H, Asano O, Hoshino Y, et al., “2-Alykynyl-8-aryl-9-methyladenines as Novel Adenosine Receptor Antagonists: Their Synthesis and Structure-Activity Relationships toward Hepatic Glucose Production Induced via Agonism of the A(2B) Receptor”, J Med Chem, 2001, 44, 170-179.
Harfenist M, Thom E, “The Influence of Structure on the Rate of Thermal Rearrangement of Aryl Propargyl Ethers to the Chromenes. The gem-Dimethyl Effect”, J Org Chem, 1972, 37/6, 841-48.
Hennion G. F. et al., “The Kinetics of the Hydrolysis of Acetylenic Chlorides and Their Reactions with Primary and Secondary Aliphatic Amines,” Journal of the American Chemical Society, 1957, pp. 2142-2145, vol. 79 (9).
Higuchi T. and Stella V., “Pro-drugs as Novel Delivery Systems,” Bioreversible Carriers in Drug Design, 1987, vol. 14, American Pharmaceutical Association and Pergamon Press.
Hiroshi Suemune et al., “Ring Cleavage and Reconstruction of Five and Six Membered Ring,” Tetrahedron Letters, 1987, pp. 3373-3376, vol. 28 (29).
Kano H, Makisumi Y, “Synthesis of Potential Anticancer Agents. I. 5-Substituted 7-Methyl-s-triazolo[4,3-a] and -tetrazolo[1.5-a]-pyrimidines”, Chem Pharm Bull, 1958, 6/6, 583-585.
Lee V. et al., “Novel Annulation Reactions: a Simple Preparation of Spirocycles and an Allylsilane Based Bifunctional Acceptor-Donor Annulating Reagent,” Tetrahedron Letters, 1986, pp. 5021-5024, vol. 27 (41), Pergamon Journals Ltd.
Lewis GF, Carpentier A, Adeli K, “Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes”, Endocr Rev, 2002, 23/2, 201-29.
Ochiai M et al., “Synthesis of ethynyl(phenyl)iodonium tetrafluoroborate. A new reagent for ethynylation of 1,3-dicarbonyl compounds,” J Chem Soc Chem Commun, 1990, pp. 118-119.
Roche, E.B., “Bioreversible Carriers in Drug Design: Theory and Application,” American Pharmaceutical Association, 1987, 13-21, Pergamon Press.
Roger et al., “Autocondensation de I'oxyde de mesityle sur magnesie a differentes pressions,” Bulletin of Chemical Society of France, 1967, pp. 3030-3037.
Rouzaud et al., “Transpositions d'hydroxy-1 cyaohexylcarbinols e t des cetones isomeres correspondantes (2e memoir®). Synthese des cetones” Bull Soc Chim Fr, 1965, pp. 2030-2037.
Smith SJ, Cases S, Jensen DR, et al., “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat”, Nat Genet, 2000, 25/1, 87-90.
Tsuji Yutaka et al., “Substituent Effects. 22. 1) The Solvolysis of a-t-Butylbenzyl Tosylates,” Bull. Chem. Soc., 1990, pp. 856-866, vol. 63 (3).
Unger RH, “Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome”, Endocrinology, 2003, 144/12, 5159-5165.
Kym Philip R.
Liu Gang
Souers Andrew J.
Xin Zhili
Abbott Laboratories
Michael & Best & Friedrich LLP
Mueller Lisa V.
Murray Jeffrey
LandOfFree
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260179